Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:1
članak: 3 od 16  
Back povratak na rezultate
Vojnosanitetski pregled
2017, vol. 74, br. 6, str. 572-581
jezik rada: engleski
vrsta rada: pregledni članak
objavljeno: 01/06/2017
doi: 10.2298/VSP151018110M
Creative Commons License 4.0
Pozitronska emisiona tomografija/kompjuterizovana tomografija primenom 18F-fluorodeoksiglukoze kod karcinoma dojke
aInstitut za onkologiju Vojvodine, Sremska Kamenica + Univerzitet u Novom Sadu, Tehnički fakultet 'Mihajlo Pupin', Zrenjanin
bHealth Care Institution for Laboratory Diagnostics 'Medlab', Novi Sad + Evropski univerzitet, Farmaceutski fakultet, Novi Sad

Sažetak

Članak ne sadrži sažetak.

Ključne reči

Reference

*** (2010) Cancer registry data of Oncology Institute of Vojvodina. Sremska Kamenica, Serbia: Oncology Institute of Vojvodina, [unpublished database]
Alberini, J., Lerebours, F., Wartski, M., Fourme, E., Le, S.E., Gontier, E., Madar, O., Cherel, P., Pecking, A. P. (2009) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer, 115(21): 5038-5047
Andrade, W.P., Lima, E.N.P., Osório, C.A.B.T., do Socorro, M.M., Baiocchi, G., Bitencourt, A.G.V., Fanelli, M.F., Damascena, A.S., Soares, F.A. (2013) Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?. European Journal of Surgical Oncology (EJSO), 39(12): 1358-1363
Aukema, T.S., Rutgers, E.J.Th., Vogel, W.V., Teertstra, H.J., Oldenburg, H.S., Vrancken, P.M.T.F.D., Wesseling, J., Russell, N.S., Valdés, O.R.A. (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. European Journal of Surgical Oncology (EJSO), 36(4): 387-392
Avril, N., Dose, J., Jänicke, F., Bense, S., Ziegler, S., Laubenbacher, C., Römer, W., Pache, H., Herz, M., Allgayer, B., Nathrath, W., Graeff, H., Schwaiger, M. (1996) Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. Journal of clinical oncology, 14(6): 1848-57
Avril, N., Dose, J., Janicke, F., Ziegler, S., Romer, W., Weber, W., Herz, M., Nathrath, W., Graeff, H., Schwaiger, M. (1996) Assessment of Axillary Lymph Node Involvement in Breast Cancer Patients With Positron Emission Tomography Using Radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose. JNCI Journal of the National Cancer Institute, 88(17): 1204-1209
Avril, N., Rosé, C.A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., Schwaiger, M. (2000) Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations. Journal of Clinical Oncology, 18(20): 3495-3502
Avril, N., Menzel, M., Dose, J., Schelling, M., Weber, W., Jänicke, F., et al. (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med, 42(1): 9-16
Basu, S., Chen, W., Tchou, J., Mavi, A., Cermik, T., Czerniecki, B., Schnall, M., Alavi, A. (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method. Cancer, 112(5): 995-1000
Baum, R.P., Przetak, C. (2001) Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med, 45(3): 257-68
Beaulieu, S., Kinahan, P., Tseng, J., Dunnwald, L.K., Schubert, E.K., Pham, P., et al. (2003) SUV varies with time after injection in (18)F-FDG PET of breast cancer: Characterization and method to adjust for time differences. J Nucl Med, 44(7): 1044-50
Berg, W.A., Weinberg, I.N., Narayanan, D., Lobrano, M.E., Ross, E., Amodei, L., Tafra, L., Adler, L.P., Uddo, J., Stein, W., Levine, E.A. (2006) High-Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression ('Positron Emission Mammography') is Highly Accurate in Depicting Primary Breast Cancer. Breast Journal, 12(4): 309-323
Berg, W.A., Madsen, K.S., Schilling, K., Tartar, M., Pisano, E.D., Larsen, L.H., Narayanan, D., Ozonoff, A., Miller, J.P., Kalinyak, J.E. (2011) Breast Cancer: Comparative Effectiveness of Positron Emission Mammography and MR Imaging in Presurgical Planning for the Ipsilateral Breast. Radiology, 258(1): 59-72
Bos, R., van Der, H.J.J.M., van Der, W.E., van Der, G.P., van Diest, P.J., Comans, E.F.I., Joshi, U., Semenza, G.L., Hoekstra, O.S., Lammertsma, A.A., Molthoff, C.F.M. (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of clinical oncology, 20(2): 379-87
Buck, A., Schirrmeister, H., Kühn, T., Shen, C., Kalker, T., Kotzerke, J., Dankerl, A., Glatting, G., Reske, S., Mattfeldt, T. (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 29(10): 1317-1323
Buck, A.K., Schirrmeister, H., Mattfeldt, T., Reske, S.N. (2004) Biological characterisation of breast cancer by means of PET. European Journal of Nuclear Medicine and Molecular Imaging, 31(0): S80-S87
Burcombe, R., Makris, A., Pittam, M., Lowe, J., Emmott, J., Wong, W. (2002) Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. European Journal of Cancer, 38(3): 375-379
Cachin, F., Prince, H. M., Hogg, A., Ware, R.E., Hicks, R.J. (2006) Powerful Prognostic Stratification By [ 18 F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy. Journal of Clinical Oncology, 24(19): 3026-3031
Carkaci, S., Macapinlac, H. A., Cristofanilli, M., Mawlawi, O., Rohren, E., Gonzalez, A.A. M., Dawood, S., Resetkova, E., Le-Petross, H. T., Yang, W.-T. (2009) Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data. Journal of Nuclear Medicine, 50(2): 231-238
Champion, L., Brain, E., Giraudet, A., Le, S.E., Wartski, M., Edeline, V., Madar, O., Bellet, D., Pecking, A., Alberini, J. (2010) Breast cancer recurrence diagnosis suspected on tumor marker rising. Cancer, 117(8): 1621-1629
Chen, X., Moore, M.O., Lehman, C.D., Mankoff, D.A., Lawton, T.J., Peacock, S., Schubert, E.K., Livingston, R.B. (2004) Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy1. Academic Radiology, 11(10): 1115-1124
Contractor, K. B., Kenny, L. M., Stebbing, J., Rosso, L., Ahmad, R., Jacob, J., Challapalli, A., Turkheimer, F., Al-Nahhas, A., Sharma, R., Coombes, R. C., Aboagye, E. O. (2011) [18F]-3'Deoxy-3'-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel. Clinical Cancer Research, 17(24): 7664-7672
Cooper, K.L., Harnan, S., Meng, Y., Ward, S.E., Fitzgerald, P., Papaioannou, D., Wyld, L., Ingram, C., Wilkinson, I.D., Lorenz, E. (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology (EJSO), 37(3): 187-198
Crippa, F., Seregni, E., Agresti, R., Chiesa, C., Pascali, C., Bogni, A., Decise, D., De, S.V., Greco, M., Grazia, D.M., Bombardieri, E. (1998) Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. European Journal of Nuclear Medicine and Molecular Imaging, 25(10): 1429-1434
Danforth, D.N., Aloj, L., Carrasquillo, J.A., Bacharach, S.L., Chow, C., Zujewski, J., Whatley, M., Galen, B., Merino, M., Neumann, R.D. (2002) The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer. Breast Cancer Research and Treatment, 75(2): 135-146
Dirisamer, A., Halpern, B.S., Flöry, D., Wolf, F., Beheshti, M., Mayerhoefer, M.E., Langsteger, W. (2010) Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. European Journal of Radiology, 73(2): 294-299
Dittmann, H., Jusufoska, A., Dohmen, B.M., Smyczek-Gargya, B., Fersis, N., Pritzkow, M., Kehlbach, R., Vonthein, R., Machulla, H.J., Bares, R. (2009) 3′-Deoxy-3′-[18F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment. Nuclear Medicine and Biology, 36(2): 163-169
Eubank, W.B., Mankoff, D.A., Schmiedl, U.P., Winter, T.C., Fisher, E.R., Olshen, A.B., Graham, M.M., Eary, J.F. (1998) Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. American Journal of Roentgenology, 171(4): 1103-1110
Eubank, W.B., Mankoff, D., Bhattacharya, M., Gralow, J., Linden, H., Ellis, G., Lindsley, S., Austin-Seymour, M., Livingston, R. (2004) Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast Cancer. American Journal of Roentgenology, 183(2): 479-486
Even-Sapir, E., Metser, U., Flusser, G., Zuriel, L., Kollender, Y., Lerman, H., Lievshitz, G., Ron, I., Mishani, E. (2004) Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. Journal of nuclear medicine, 45(2): 272-8
Filippi, V., Malamitsi, J., Vlachou, F., Laspas, F., Georgiou, E., Prassopoulos, V., Andreou, J. (2011) The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nuclear Medicine Communications, 32(2): 85-90
Fisher, E.R., Wang, J., Bryant, J., Fisher, B., Mamounas, E., Wolmark, N. (2002) Pathobiology of preoperative chemotherapy. Cancer, 95(4): 681-695
Fueger, B.J., Weber, W.A., Quon, A., Crawford, T.L., Allen-Auerbach, M. S., Halpern, B. S., Ratib, O., Phelps, M.E., Czernin, J. (2005) Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients. Molecular Imaging and Biology, 7(5): 369-376
Gil-Rendo, A., Martínez-Regueira, F., Zornoza, G., García-Velloso, M. J., Beorlegui, C., Rodriguez-Spiteri, N. (2009) Association between [ 18 F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. British Journal of Surgery, 96(2): 166-170
Gil-Rendo, A., Zornoza, G., García-Velloso, M. J., Regueira, F. M., Beorlegui, C., Cervera, M. (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. British Journal of Surgery, 93(6): 707-712
Grassetto, G., Fornasiero, A., Otello, D., Bonciarelli, G., Rossi, E., Nashimben, O., Minicozzi, A.M., Crepaldi, G., Pasini, F., Facci, E., Mandoliti, G., Marzola, M.C., Al-Nahhas, A., Rubello (2011) 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study. European Journal of Radiology, 80(3): 828-833
Groheux, D., Giacchetti, S., Moretti, J., Porcher, R., Espié, M., Lehmann-Che, J., de Roquancourt, A., Hamy, A., Cuvier, C., Vercellino, L., Hindié, E. (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 38(3): 426-435
Groheux, D., Moretti, J., Baillet, G., Espie, M., Giacchetti, S., Hindie, E., Hennequin, C., Vilcoq, J., Cuvier, C., Toubert, M., Filmont, J., Sarandi, F., Misset, J. (2008) Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. International journal of radiation oncology, biology, physics, 71(3): 695-704
Hendrickson, K., Phillips, M., Smith, W., Peterson, L., Krohn, K., Rajendran, J. (2011) Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiotherapy and oncology, 101(3): 369-75
Heusner, T. A., Kuemmel, S., Umutlu, L., Koeninger, A., Freudenberg, L. S., Hauth, E. A.M., Kimmig, K. R., Forsting, M., Bockisch, A., Antoch, G. (2008) Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography. Journal of Nuclear Medicine, 49(8): 1215-1222
Hussain, S.A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., Murray, P.G., Perunovic, B., Anwar, M.S., Billingham, L., James, N.D., Spooner, D., Poole, C.J., Rea, D.W., Palmer, D.H. (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer, 96(1): 104-109
Ikenaga, N., Otomo, N., Toyofuku, A., Ueda, Y., Toyoda, K., Hayashi, T., et al. (2007) Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg, 73(11): 1151-7
Institute of Public Health of Serbia Dr Milan Jovanović Batut (2015) Cancer incidence and mortality in central Serbia 2012. [cited 2015 Aug 17]. Available from: http://www.batut.org.rs/index.php
Jung, S., Kim, S., Nam, B., Min, S.Y., Lee, S.J., Park, C., Kwon, Y., Kim, E., Ko, K.L., Park, I.H., Lee, K.S., Shin, K.H., Lee, S., Kim, S.W., Kang, H., Ro, J. (2010) Prognostic Impact of [18F] FDG-PET in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 17(1): 247-253
Keam, B., Im, S., Koh, Y., Han, S., Oh, D., Cho, N., Kim, J.H., Han, W., Kang, K.W., Moon, W.K., Kim, T., Park, I.A., Noh, D., Chung, J., Bang, Y. (2011) Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer, 11(1):
Kim, S.-J., Kim, S.-k., Lee, E. S., Ro, J., Kang, S. h. (2004) Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Annals of Oncology, 15(9): 1352-1357
Kinahan, P.E., Fletcher, J.W. (2010) Positron Emission Tomography-Computed Tomography Standardized Uptake Values in Clinical Practice and Assessing Response to Therapy. Seminars in Ultrasound, CT and MRI, 31(6): 496-505
Kolesnikov-Gauthier, H., Vanlemmens, L., Baranzelli, M., Vennin, P., Servent, V., Fournier, C., Carpentier, P., Bonneterre, J. (2012) Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast cancer research and treatment, 131(2): 517-25
Kumar, R., Chauhan, A., Zhuang, H., Chandra, P., Schnall, M., Alavi, A. (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Research and Treatment, 98(3): 267-274
Kurland, B. F., Peterson, L. M., Lee, J. H., Linden, H. M., Schubert, E. K., Dunnwald, L. K., Link, J. M., Krohn, K. A., Mankoff, D. A. (2011) Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET. Journal of Nuclear Medicine, 52(10): 1541-1549
Levine, E.A., Freimanis, R.I., Perrier, N.D., Morton, K., Lesko, N.M., Bergman, S., Geisinger, K.R., Williams, R.C., Sharpe, C., Zavarzin, V., Weinberg, I.N., Stepanov, P.Y., Beylin, D., Lauckner, K. (2003) Positron Emission Mammography: Initial Clinical Results. Annals of Surgical Oncology, 10(1): 86-91
Linden, H. M., Kurland, B. F., Peterson, L. M., Schubert, E. K., Gralow, J. R., Specht, J. M., Ellis, G. K., Lawton, T. J., Livingston, R. B., Petra, P. H., Link, J. M., Krohn, K. A., Mankoff, D. A. (2011) Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 17(14): 4799-4805
Litmanovich, D., Gourevich, K., Israel, O., Gallimidi, Z. (2009) Unexpected foci of 18F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance. European Journal of Nuclear Medicine and Molecular Imaging, 36(10): 1558-1564
Lubberink, M., Direcks, W., Emmering, J., Tinteren, H., Hoekstra, O.S., Hoeven, J.J., et al. (2012) Validity of simplified 3-deoxy-3-[18F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer. Mol Imaging Biol, 14(6); 777-82
Lyman, G.H. (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol, 23(30): 7703-20
Manohar, K., Mittal, B.R., Senthil, R., Kashyap, R., Bhattacharya, A., Singh, G. (2012) Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nuclear Medicine Communications, 33(6): 591-596
Mavi, A., Cermik, T. F., Urhan, M., Puskulcu, H., Basu, S., Yu, J. Q., Zhuang, H., Czerniecki, B., Alavi, A. (2007) The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions. Journal of Nuclear Medicine, 48(8): 1266-1272
Murthy, K., Aznar, M., Thompson, C.J., Loutfi, A., Lisbona, R., Gagnon, J.H. (2000) Results of preliminary clinical trials of the positron emission mammography system PEM-I: A dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med, 41(11): 1851−8
Nakai, T., Okuyama, C., Kubota, T., Yamada, K., Ushijima, Y., Taniike, K., Suzuki, T., Nishimura, T. (2005) Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 32(11): 1253-1258
Osborne, J. R., Port, E., Gonen, M., Doane, A., Yeung, H., Gerald, W., Cook, J. B., Larson, S. (2010) 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis. Journal of Nuclear Medicine, 51(4): 543-550
Pan, L., Han, Y., Sun, X., Liu, J., Gang, H. (2010) FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 136(7): 1007-1022
Paquette, M., Phoenix, S., Ouellet, R., Langlois, R., van Lier, J.E., Turcotte, É.E., Bénard, F., Lecomte, R. (2013) Assessment of the Novel Estrogen Receptor PET Tracer 4-Fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4FMFES) by PET Imaging in a Breast Cancer Murine Model. Molecular Imaging and Biology, 15(5): 625-632
Park, S.H., Moon, W.K., Cho, N., Chang, J.M., Im, S., Park, I.A., Kang, K.W., Han, W., Noh, D. (2012) Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. European Radiology, 22(1): 18-25
Pennant, M., Takwoingi, Y., Pennant, L., Davenport, C., Fry-Smith, A., Eisinga, A., Andronis, L., Arvanitis, T., Deeks, J., Hyde, C. (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment, 14(50):
Peterson, L.M., Kurland, B.F., Link, J.M., Schubert, E.K., Stekhova, S., Linden, H.M., Mankoff, D.A. (2011) Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nuclear Medicine and Biology, 38(7): 969-978
Piperkova, E., Raphael, B., Altinyay, M.E., Castellon, I., Libes, R., Sandella, N., Heiba, S., Abdel-Dayem, H. (2007) Impact of PET/CT in Comparison With Same Day Contrast Enhanced CT in Breast Cancer Management. Clinical Nuclear Medicine, 32(6): 429-434
Radan, L., Ben-Haim, S., Bar-Shalom, R., Guralnik, L., Israel, O. (2006) The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 107(11): 2545-2551
Rajendran, J. G. (2004) Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging. Clinical Cancer Research, 10(7): 2245-2252
Rosen, E.L., Turkington, T.G., Soo, M.S., Baker, J.A., Coleman, R. E. (2005) Detection of Primary Breast Carcinoma with a Dedicated, Large-Field-of-View FDG PET Mammography Device: Initial Experience. Radiology, 234(2): 527-534
Rosen, E.L., Eubank, W.B., Mankoff, D.A. (2007) FDG PET, PET/CT, and Breast Cancer Imaging. RadioGraphics, 27(suppl_1): S215-S229
Rousseau, C., Devillers, A., Sagan, C., Ferrer, L., Bridji, B., Campion, L., Ricaud, M., Bourbouloux, E., Doutriaux, I., Clouet, M., Berton-Rigaud, D., Bouriel, C., Delecroix, V., Ga (2006) Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [ 18 F]Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 24(34): 5366-5372
Samson, D.J., Flamm, C.R., Pisano, E.D., Aronson, N. (2002) Should FDG PET be used to Decide Whether a Patient with an Abnormal Mammogram or Breast Finding at Physical Examination should Undergo Biopsy?. Academic Radiology, 9(7): 773-783
Schelling, M., Avril, N., Nährig, J., Kuhn, W., Römer, W., Sattler, D., Werner, M., Dose, J., Jänicke, F., Graeff, H., Schwaiger, M. (2000) Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. Journal of clinical oncology, 18(8): 1689-95
Schirrmeister, H. (2007) Detection of Bone Metastases in Breast Cancer by Positron Emission Tomography. Radiologic Clinics of North America, 45(4): 669-676
Segaert, I., Mottaghy, F., Ceyssens, S., De, W.W., Stroobants, S., Van, O.C., Van, L.E., Wildiers, H., Paridaens, R., Vergote, I., Christiaens, M., Neven, P. (2010) Additional Value of PET-CT in Staging of Clinical Stage IIB and III Breast Cancer. Breast Journal, 16(6): 617-624
Shimoda, W., Hayashi, M., Murakami, K., Oyama, T., Sunagawa, M. (2007) The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer, 14(3): 260-268
Siegel, R.L., Miller, K.D., Jemal, A. (2015) Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65(1): 5-29
Tatsumi, M., Cohade, C., Mourtzikos, K.A., Fishman, E.K., Wahl, R.L. (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. European journal of nuclear medicine and molecular imaging, 33(3): 254-62
Tehrani, O.S., Shields, A.F. (2013) PET imaging of proliferation with pyrimidines. Journal of nuclear medicine, 54(6): 903-12
van der Hage, J.A., van de Velde, C.J.H., Julien, J., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L. (2001) Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902. Journal of Clinical Oncology, 19(22): 4224-4237
van Kruchten, M., Glaudemans, A. W. J. M., de Vries, E. F. J., Beets-Tan, R. G. H., Schroder, C. P., Dierckx, R. A., de Vries, E. G. E., Hospers, G. A. P. (2012) PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. Journal of Nuclear Medicine, 53(2): 182-190
Veronesi, U., De, C.C., Galimberti, V., Fernandez, J., Rotmensz, N., Viale, G., Spano, G., Luini, A., Intra, M., Veronesi, P., Berrettini, A., Paganelli, G. (2006) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Annals of Oncology, 18(3): 473-478
Wahl, R.L., Zasadny, K., Helvie, M., Hutchins, G.D., Weber, B., Cody, R. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. Journal of Clinical Oncology, 11(11): 2101-2111
Wahl, R.L., Siegel, B.A., Coleman, R. E., Gatsonis, C.G. (2004) Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. Journal of Clinical Oncology, 22(2): 277-285